文献速递胸部肿瘤

组织学、肿瘤体积与放疗剂量预测NSCLC立体定向消融放疗后结局

Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy.
PubMed 文献 · J Thorac Oncol · 2018-06-27

该研究纳入508例早期NSCLC患者(561个病灶),其中442例(482个病灶)有完整剂量学信息,接受3–5次立体定向消融放疗。中位随访6.7年,3年野内控制率88.1%、受累肺叶控制率80.0%、总生存率49.4%、无进展生存率37.2%。GTV和组织学与受累肺叶失败独立相关;GTV和GTV剂量(BED10 cutoff 110 Gy)与野内失败独立相关。鳞癌中较低处方剂量与更差野内控制相关,腺癌中未见差异。

要点

  • GTV每增加1 mL与受累肺叶失败风险独立相关(HR=1.01,p=0.0044)。
  • GTV(HR=1.013,p=0.001)和GTV剂量(BED10 cutoff 110 Gy,HR=2.380,p=0.0084)与野内失败独立相关。
  • 鳞癌中12 Gy×4或10 Gy×5较18 Gy或20 Gy×3野内控制更差(HR=3.530,p=0.0447),腺癌中无差异。

核心结论

  • 在缺乏I级证据的情况下,应考虑GTV和组织学以个体化立体定向消融放疗剂量。
  • 若正常组织耐受允许,鳞癌应避免较低处方剂量(如12 Gy×4或10 Gy×5)。

研究设计与样本

  • 回顾性研究纳入2000–2016年间508例早期NSCLC患者共561个病灶,其中442例482个病灶有完整剂量学信息。
  • 患者接受3–5次立体定向消融放疗,主要终点为野内肿瘤控制(删失于死亡或进展),同时评估受累肺叶控制。

主要发现

  • 中位随访6.7年,3年野内控制率88.1%、受累肺叶控制率80.0%、总生存率49.4%、无进展生存率37.2%。
  • GTV(每mL HR=1.01,p=0.0044)和组织学(p=0.0225)与受累肺叶失败独立相关。
  • GTV(HR=1.013,p=0.001)和GTV剂量(BED10 cutoff 110 Gy,HR=2.380,p=0.0084)与野内失败独立相关。
  • 鳞癌中较低处方剂量(12 Gy×4或10 Gy×5 vs 18 Gy或20 Gy×3)与更差野内控制相关(HR=3.530,p=0.0447,倾向评分匹配确认),且独立于GTV(每mL HR=1.014,95%CI 1.005–1.022,p=0.0012)。
  • 腺癌中上述剂量分组间野内控制无差异(p=0.12和p=0.31)。

关键数值与推荐

  • GTV每增加1 mL,受累肺叶失败风险HR=1.01(p=0.0044)。
  • GTV每增加1 mL,野内失败风险HR=1.013(p=0.001)。
  • GTV剂量BED10 cutoff 110 Gy与野内失败相关HR=2.380(p=0.0084)。
  • 鳞癌中较低处方剂量与野内失败HR=3.530(p=0.0447),GTV每mL HR=1.014(95%CI 1.005–1.022,p=0.0012)。

临床怎么用

  • 选择立体定向消融放疗剂量时应结合GTV和组织学进行个体化。
  • 对鳞癌患者,若正常组织耐受允许,应避免使用12 Gy×4或10 Gy×5等较低处方剂量。

局限性

  • 缺乏I级证据,结论基于回顾性研究。
  • 部分患者(508例中442例)无完整剂量学信息,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: It remains unclear if histology should be independently considered when choosing stereotactic ablative body radiotherapy dose prescriptions for NSCLC. METHODS: The study population included 508 patients with 561 lesions between 2000 and 2016, of which 442 patients with 482 lesions had complete dosimetric information. Eligible patients had histologically or clinically diagnosed early-stage NSCLC and were treated with 3 to 5 fractions. The primary endpoint was in-field tumor control censored by either death or progression. Involved lobe control was also assessed. RESULTS: At 6.7 years median follow-up, 3-year in-field control, involved lobe control, overall survival, and progression-free survival rates were 88.1%, 80.0%, 49.4%, and 37.2%, respectively. Gross tumor volume (GTV) (hazard ratio [HR] = 1.01 per mL, p = 0.0044) and histology (p = 0.0225) were independently associated with involved lobe failure. GTV (HR = 1.013, p = 0.001) and GTV dose (cutoff of 110 Gy, biologically effective dose with α/β = 10 [BED10], HR = 2.380, p = 0.0084) were independently associated with in-field failure. For squamous cell carcinomas, lower prescription doses were associated with worse in-field control (12 Gy × 4 or 10 Gy × 5 versus 18 Gy or 20 Gy × 3: HR = 3.530, p = 0.0447, confirmed by propensity score matching) and was independent of GTV (HR = 1.014 per mL, 95% confidence interval: 1.005-1.022, p = 0.0012). For adenocarcinomas, there were no differences in in-field control observed using the above dose groupings (p = 0.12 and p = 0.31, respectively). CONCLUSIONS: In the absence of level I data, GTV and histology should be considered to personalize radiation dose for stereotactic ablative body radiotherapy. We suggest lower prescription doses (i.e., 12 Gy × 4 or 10 G × 5) should be avoided for squamous cell carcinomas if normal tissue tolerances are met.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Shiue K, Cerra-Franco A, Shapiro R, et al. Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol. 2018. PMID: 29959060. doi:10.1016/j.jtho.2018.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。